Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10377484" target="_blank" >RIV/00216208:11130/18:10377484 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/18:00104196 RIV/00216208:11140/18:10377484 RIV/00216208:11150/18:10377484 RIV/61989592:15110/18:73590069 and 5 more

Result on the web

<a href="https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.004" target="_blank" >https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.004" target="_blank" >10.1016/j.jstrokecerebrovasdis.2018.05.004</a>

Result language

angličtina

Original language name

Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience

Original language description

Background: Intravenous thrombolysis (IVT) is contraindicated in patients with acute ischemic stroke (AIS) using oral anticoagulants. A specific human monoclonal antibody was introduced to reverse immediately the anticoagulation effect of the direct inhibitor of thrombin, dabigatran. Until now, mostly individual cases presenting with successful IVT after a reversal of dabigatran anticoagulation in patients with AIS were published. Thus, we aimed to report real-world data from clinical practice. Methods: Patients with AIS on dabigatran treated with IVT after antidote reversal were enrolled in the retrospective nationwide study. Neurological deficit was scored using the National Institutes of Health Stroke Scale (NIHSS) and 90-day clinical outcome using modified Rankin scale (mRS) with a score 0-2 for a good outcome. Intracerebral hemorrhage (ICH) was defined as a presence of any sign of bleeding on control imaging after IVT, and symptomatic intracerebral hemorrhage (SICH) was assessed according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria. Results: In total, 13 patients (7 men, mean age 70.0 +/- 9.1 years) with a median NIHSS admission score of 7 points were analyzed. Of these patients, 61.5% used 2 x 150 mg of dabigatran daily. Antidote was administrated 427 +/- 235 minutes after the last intake of dabigatran, with a mean activated prothrombin time of 38.1 +/- 27.8 seconds and a mean thrombin time of 72.2 +/- 56.1 seconds. Of the 13 patients, 2 had ICH and 1 had SICH, and no other bleeding complications were observed after IVT. Of the total number of patients, 76.9% had a good 3-month clinical outcome and 3 patients (23.1%) died. Recurrent ischemic stroke occurred in 2 patients (15.4%). Conclusion: The data presented in the study support the safety and efficacy of IVT after the reversal of the anticoagulation effect of dabigatran with antidote in a real-world clinical practice.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Stroke and Cerebrovascular Diseases

ISSN

1052-3057

e-ISSN

—

Volume of the periodical

27

Issue of the periodical within the volume

9

Country of publishing house

US - UNITED STATES

Number of pages

5

Pages from-to

2479-2483

UT code for WoS article

000441086000034

EID of the result in the Scopus database

2-s2.0-85047416159